DIFFUSION PHARMACEUTICALS INC
Compare this stock
DFFN Stock Report Card
$
28%
Performance
Score:
10/100
DFFN returned -61.80% in the last 12 months. Based on SPY's performance of -8.71%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
Score:
75/100
1 analysts offer 12-month price targets for DFFN. Together, they have an average target of 0, the most optimistic target put DFFN at 0 within 12-months and the most pessimistic has DFFN at 0. These analyst ratings are from our partners at Financial Modeling Prep (https://site.financialmodelingprep.com/) and Alpha Vantage (https://www.alphavantage.co/).
Technicals
Score:
14/100
DFFN receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.
Earnings
Score:
10/100
DFFN has missed earnings 7 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 20 quarters, DFFN has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
Score:
48/100
DFFN has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.
DIFFUSION PHARMACEUTICALS INC Summary
Nasdaq / DFFN
Healthcare
Biotechnology
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
DFFN scored poorly on our reportcard. Here are some similar companies and how they performed.
